- Home
- People
- CLINUVEL news
Dr Pilar Bilbao — CLINUVEL’s DNA Repair Program
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the global relevance of the Company’s DNA Repair program, as well as the significance of the recently released first results from the CUV151 study in healthy volunteers.CLINUVEL newsCLINUVEL: developing innovative treatments for stroke patients
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, provides an overview of results from the first clinical study of CLINUVEL’s drug afamelanotide in arterial ischaemic stroke (AIS) patients, then discusses the impact for patients’ lives and gives an update on the next steps in the clinical program for AIS.CLINUVEL newsNasdaq TradeTalks Interview
CLINUVEL’s Managing Director, Dr Philippe Wolgen, speaks with Jill Malandrino on Nasdaq TradeTalks, 26 October 2021.PeopleDr Pilar Bilbao discusses possible solutions for stroke patients
Ischaemic strokes cause irreversible damage. They begin suddenly and the damage escalates if the stroke is not treated quickly.
- R&D
- CLINUVEL news
Dr Pilar Bilbao — CLINUVEL’s DNA Repair Program
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the global relevance of the Company’s DNA Repair program, as well as the significance of the recently released first results from the CUV151 study in healthy volunteers.CLINUVEL newsCLINUVEL: developing innovative treatments for stroke patients
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, provides an overview of results from the first clinical study of CLINUVEL’s drug afamelanotide in arterial ischaemic stroke (AIS) patients, then discusses the impact for patients’ lives and gives an update on the next steps in the clinical program for AIS.CLINUVEL newsDr Pilar Bilbao – Update on CLINUVEL’s Stroke Program
In January 2022, CLINUVEL announced that it had completed enrolment in its world-first study of afamelanotide as a treatment for arterial...PeopleDr Pilar Bilbao discusses possible solutions for stroke patients
Ischaemic strokes cause irreversible damage. They begin suddenly and the damage escalates if the stroke is not treated quickly.
- Publications
- Publications
The Weekend Effect – A Worrying Truth or Myth?
Reduced staff over the weekends is the norm for many retail shops, but what about in healthcare? A number of reviews have...PublicationsIs skin cancer in your job description?
Those of us working from offices, or our own homes, aren’t expecting danger pay. However, what about those who have jobs that heighten the risk of getting skin...PublicationsTomatoes and carrots… photoprotection from within?
Most of us have been spun a myth that eating our crusts will make our hair shiny, and that we should...PublicationsHas COVID-19 Had an Effect on Sun Protection Behaviours?
Quarantine fatigue amongst the general public may result in a higher incidence rate of sunburn, according to a recent analysis of...
- Finance & investing
- CLINUVEL news
CLINUVEL PHARMACEUTICALS LTD Annual General Meeting 2022
On October 26th 2022 CLINUVEL PHARMACEUTICALS held its 2022 Annual General MeetingCLINUVEL newsCLINUVEL Investor Webinar on FY2022 financial results
In an investor and analyst webinar hosted by CLINUVEL, Mr Malcolm Bull, Head of Investor Relations, is joined by Mr Darren Keamy, Chief Financial Officer, and Dr Philippe Wolgen, Managing Director, in discussing the financial results for the year ended 30 June 2022 and the Company’s plans for FY2023 and beyond.CLINUVEL newsA CLINUVEL Webcast on Market Position, Financial Management and Growth
In a webcast addressed to shareholders, CLINUVEL’s Managing Director, Dr Philippe Wolgen, covers CLINUVEL’s market position, financial management and the Group’s unfolding growth and expansion strategy.CLINUVEL newsOperations Update I – 2022 Financial Results Webinar
CLINUVEL’s Chief Financial Officer, Darren Keamy, and Director of Global Operations, Lachlan Hay, discuss the financial results for the half year ended 31 December 2021, the Company’s multi-pronged growth and expansion strategy and the activities of the Pharmaceuticals and Healthcare Solutions Divisions.